Cardiac Fibrosis in Patients With Atrial Fibrillation: Mechanisms and Clinical Implications.

Atrial fibrillation (AF) is associated with structural, electrical, and contractile remodeling of the atria. Development and progression of atrial fibrosis is the hallmark of structural remodeling in AF and is considered the substrate for AF perpetuation. In contrast, experimental and clinical data on the effect of ventricular fibrotic processes in the pathogenesis of AF and its complications are controversial. Ventricular fibrosis seems to contribute to abnormalities in cardiac relaxation and contractility and to the development of heart failure, a common finding in AF. Given that AF and heart failure frequently coexist and that both conditions affect patient prognosis, a better understanding of the mutual effect of fibrosis in AF and heart failure is of particular interest. In this review paper, we provide an overview of the general mechanisms of cardiac fibrosis in AF, differences between fibrotic processes in atria and ventricles, and the clinical and prognostic significance of cardiac fibrosis in AF.

[1]  V. Petrov,et al.  Transforming growth factor-beta 1-induced collagen production in cultures of cardiac fibroblasts is the result of the appearance of myofibroblasts. , 2002, Methods and findings in experimental and clinical pharmacology.

[2]  K. Schlüter,et al.  TGFβ receptor activation enhances cardiac apoptosis via SMAD activation and concomitant NO release , 2011, Journal of cellular physiology.

[3]  J. D’Armiento,et al.  Disruption of the myocardial extracellular matrix leads to cardiac dysfunction. , 2000, The Journal of clinical investigation.

[4]  S. Miyagawa,et al.  Impact of microRNA Expression in Human Atrial Tissue in Patients with Atrial Fibrillation Undergoing Cardiac Surgery , 2013, PloS one.

[5]  Arantxa González,et al.  Increased Collagen Type I Synthesis in Patients With Heart Failure of Hypertensive Origin: Relation to Myocardial Fibrosis , 2004, Circulation.

[6]  Michael F Swartz,et al.  Dominant Frequency Increase Rate Predicts Transition from Paroxysmal to Long-Term Persistent Atrial Fibrillation , 2014, Circulation.

[7]  Xiaobin Luo,et al.  Role for MicroRNA-21 in Atrial Profibrillatory Fibrotic Remodeling Associated With Experimental Postinfarction Heart Failure , 2012, Circulation. Arrhythmia and electrophysiology.

[8]  Andrew J Taylor,et al.  Magnetic resonance post-contrast T1 mapping in the human atrium: validation and impact on clinical outcome after catheter ablation for atrial fibrillation. , 2014, Heart rhythm.

[9]  Yuan Zhang,et al.  Obesity results in progressive atrial structural and electrical remodeling: implications for atrial fibrillation. , 2013, Heart rhythm.

[10]  B. Khandheria,et al.  Role of imaging in assessment of atrial fibrosis in patients with atrial fibrillation: state-of-the-art review. , 2014, European heart journal cardiovascular Imaging.

[11]  A. Goette,et al.  Atrial fibrillation and rapid acute pacing regulate adipocyte/adipositas-related gene expression in the atria. , 2015, International journal of cardiology.

[12]  Yun Zhang,et al.  Myocardial ultrasonic integrated backscatter analysis in patients with chronic atrial fibrillation , 2010, The International Journal of Cardiovascular Imaging.

[13]  Chien-Huang Lin,et al.  Elevated expression of connective tissue growth factor in human atrial fibrillation and angiotensin II-treated cardiomyocytes. , 2011, Circulation journal : official journal of the Japanese Circulation Society.

[14]  Michael F Swartz,et al.  Elevated pre-operative serum peptides for collagen I and III synthesis result in post-surgical atrial fibrillation. , 2012, Journal of the American College of Cardiology.

[15]  A. Camm,et al.  Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. , 2011, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[16]  R. McKelvie,et al.  Relation of Peripheral Collagen Markers to Death and Hospitalization in Patients With Heart Failure and Preserved Ejection Fraction: Results of the I-PRESERVE Collagen Substudy , 2011, Circulation. Heart failure.

[17]  Leif Hove-Madsen,et al.  PITX2 Insufficiency Leads to Atrial Electrical and Structural Remodeling Linked to Arrhythmogenesis , 2011, Circulation. Cardiovascular genetics.

[18]  Gary R. Grotendorst Connective tissue growth factor: a mediator of TGF-β action on fibroblasts , 1997 .

[19]  M. Chung,et al.  Association of Left Atrial Endothelin-1 With Atrial Rhythm, Size, and Fibrosis in Patients With Structural Heart Disease , 2010, Circulation. Arrhythmia and electrophysiology.

[20]  Jun-zhu Chen,et al.  Possible involvement of fibrocytes in atrial fibrosis in patients with chronic atrial fibrillation. , 2014, Circulation journal : official journal of the Japanese Circulation Society.

[21]  L. Ling,et al.  Diffuse ventricular fibrosis in atrial fibrillation: noninvasive evaluation and relationships with aging and systolic dysfunction. , 2012, Journal of the American College of Cardiology.

[22]  Gary R. Grotendorst Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. , 1997, Cytokine & growth factor reviews.

[23]  S. Hazen,et al.  Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation , 2010, Nature Medicine.

[24]  Jeroen J. Bax,et al.  Non-invasive imaging in atrial fibrillation: focus on prognosis and catheter ablation , 2014, Heart.

[25]  A. Capucci,et al.  Sleep-Disordered Breathing and Atrial Fibrillation: Review of the Evidence , 2015, Cardiology in review.

[26]  J. Molkentin,et al.  Periostin as a Heterofunctional Regulator of Cardiac Development and Disease , 2008, Current genomics.

[27]  Vijay Devabhaktuni,et al.  Long-Term Frequency Gradients During Persistent Atrial Fibrillation in Sheep Are Associated With Stable Sources in the Left Atrium , 2012, Circulation. Arrhythmia and electrophysiology.

[28]  Jifeng Zhang,et al.  Integrated analysis of microRNA and mRNA expression profiles in the left atrium of patients with nonvalvular paroxysmal atrial fibrillation: Role of miR-146b-5p in atrial fibrosis. , 2015, Heart rhythm.

[29]  Gernot Plank,et al.  Mechanistic inquiry into the role of tissue remodeling in fibrotic lesions in human atrial fibrillation. , 2013, Biophysical journal.

[30]  S. Nattel,et al.  Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. , 2014, Journal of the American College of Cardiology.

[31]  Reza Nezafat,et al.  Recurrence of atrial fibrillation correlates with the extent of post-procedural late gadolinium enhancement: a pilot study. , 2009, JACC. Cardiovascular imaging.

[32]  Shenming Wang,et al.  Atrial Fibrillation Induces Myocardial Fibrosis Through Angiotensin II Type 1 Receptor–Specific Arkadia-Mediated Downregulation of Smad7 , 2011, Circulation research.

[33]  Hiroshi Ashikaga,et al.  Association of left atrial function and left atrial enhancement in patients with atrial fibrillation: cardiac magnetic resonance study. , 2015, Circulation. Cardiovascular imaging.

[34]  Michael Jerosch-Herold,et al.  Myocardial extracellular volume fraction from T1 measurements in healthy volunteers and mice: relationship to aging and cardiac dimensions. , 2013, JACC. Cardiovascular imaging.

[35]  A. J. Valente,et al.  Angiotensin II stimulates cardiac fibroblast migration via the differential regulation of matrixins and RECK. , 2013, Journal of molecular and cellular cardiology.

[36]  K. Gatter,et al.  Atrial fibrillation is associated with cardiac hypoxia. , 2010, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[37]  Hongli Li,et al.  Expression of miR-133 and miR-30 in chronic atrial fibrillation in canines. , 2012, Molecular medicine reports.

[38]  I. V. Van Gelder,et al.  University of Groningen Atrial Remodeling Is Directly Related to End-Diastolic Left Ventricular Pressure in a Mouse Model of Ventricular Pressure Overload , 2013 .

[39]  S. Nattel,et al.  Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. , 2008, Journal of the American College of Cardiology.

[40]  K. Griendling,et al.  Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. , 2007, American journal of physiology. Cell physiology.

[41]  Chunxiang Zhang,et al.  MicroRNA-21 protects against the H(2)O(2)-induced injury on cardiac myocytes via its target gene PDCD4. , 2009, Journal of molecular and cellular cardiology.

[42]  J. Svendsen,et al.  Atrial fibrillation: the role of common and rare genetic variants , 2022 .

[43]  Jean-Claude Tardif,et al.  Atrial fibrillation promotion with long-term repetitive obstructive sleep apnea in a rat model. , 2014, Journal of the American College of Cardiology.

[44]  R. Duisters,et al.  MIRNA-133 AND MIRNA-30 REGULATE CONNECTIVE TISSUE GROWTH FACTOR: IMPLICATIONS FOR A ROLE OF MIRNAS IN MYOCARDIAL MATRIX REMODELING , 2013 .

[45]  Yijiang Chen,et al.  OPG/RANK/RANKL Axis in Stabilization of Spontaneously Restored Sinus Rhythm in Permanent Atrial Fibrillation Patients after Mitral Valve Surgery , 2012, Cardiology.

[46]  T. Chao,et al.  Transforming growth factor-β1 level and outcome after catheter ablation for nonparoxysmal atrial fibrillation. , 2013, Heart rhythm.

[47]  Nassir Marrouche,et al.  Association of Atrial Fibrosis Quantified Using LGE‐MRI with Atrial Appendage Thrombus and Spontaneous Contrast on Transesophageal Echocardiography in Patients with Atrial Fibrillation , 2013, Journal of cardiovascular electrophysiology.

[48]  Joshua J. E. Blauer,et al.  Detection and Quantification of Left Atrial Structural Remodeling With Delayed-Enhancement Magnetic Resonance Imaging in Patients With Atrial Fibrillation , 2009, Circulation.

[49]  Q. Xie,et al.  Meta-analysis Identifies Serum C-Reactive Protein as an Indicator of Atrial Fibrillation Risk After Coronary Artery Bypass Graft , 2016, American journal of therapeutics.

[50]  J. Cleland,et al.  Association of galectin‐3 and fibrosis markers with long‐term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE‐HF (Cardiac Resynchronization in Heart Failure) trial , 2012, European journal of heart failure.

[51]  W. Rottbauer,et al.  MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts , 2008, Nature.

[52]  Jin Wei,et al.  Ageing related periostin expression increase from cardiac fibroblasts promotes cardiomyocytes senescent. , 2014, Biochemical and biophysical research communications.

[53]  S Nattel,et al.  Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. , 1999, Circulation.

[54]  G. Hansson,et al.  Overexpression of inducible nitric oxide synthase by neointimal smooth muscle cells. , 1998, Circulation research.

[55]  D. Corradi Atrial fibrillation from the pathologist's perspective. , 2014, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[56]  R. Blankstein,et al.  Myocardial extracellular volume expansion and the risk of recurrent atrial fibrillation after pulmonary vein isolation. , 2014, JACC. Cardiovascular imaging.

[57]  J. Nerbonne,et al.  MicroRNA-133a Protects Against Myocardial Fibrosis and Modulates Electrical Repolarization Without Affecting Hypertrophy in Pressure-Overloaded Adult Hearts , 2010, Circulation Research.

[58]  Prashanthan Sanders,et al.  Electrical Remodeling of the Atria in Congestive Heart Failure: Electrophysiological and Electroanatomic Mapping in Humans , 2003, Circulation.

[59]  Y. Okumura,et al.  Transthoracic echocardiographic backscatter-based assessment of left atrial remodeling involving left atrial and ventricular fibrosis in patients with atrial fibrillation. , 2014, International journal of cardiology.

[60]  E. Kholmovski,et al.  Association of left atrial fibrosis detected by delayed-enhancement magnetic resonance imaging and the risk of stroke in patients with atrial fibrillation. , 2011, Journal of the American College of Cardiology.

[61]  S. Nattel,et al.  Differential Behaviors of Atrial Versus Ventricular Fibroblasts: A Potential Role for Platelet-Derived Growth Factor in Atrial-Ventricular Remodeling Differences , 2008, Circulation.

[62]  M. Mayr,et al.  Targeting myocardial remodelling to develop novel therapies for heart failure , 2014, European Journal of Heart Failure.

[63]  Nazem Akoum,et al.  Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. , 2014, JAMA.

[64]  Marlena Maziarz,et al.  Circulating fibrosis biomarkers and risk of atrial fibrillation: The Cardiovascular Health Study (CHS). , 2014, American heart journal.

[65]  Stanley Nattel,et al.  The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. , 2014, Circulation research.

[66]  A. McLellan,et al.  Sinus rhythm restores ventricular function in patients with cardiomyopathy and no late gadolinium enhancement on cardiac magnetic resonance imaging who undergo catheter ablation for atrial fibrillation. , 2013, Heart rhythm.

[67]  Douglas L. Jones,et al.  Chronic rapid atrial pacing. Structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation. , 1995, Circulation.

[68]  J. Brugada,et al.  Atrial fibrosis in a chronic murine model of obstructive sleep apnea: mechanisms and prevention by mesenchymal stem cells , 2014, Respiratory Research.

[69]  M. Rienstra,et al.  Relation between soluble ST2, growth differentiation factor-15, and high-sensitivity troponin I and incident atrial fibrillation. , 2014, American heart journal.

[70]  C. Loewe,et al.  Time course of markers of tissue repair after ablation of atrial fibrillation and their relation to left atrial structural changes and clinical ablation outcome. , 2011, International journal of cardiology.

[71]  D. Levy,et al.  Galectin 3 and incident atrial fibrillation in the community. , 2014, American heart journal.

[72]  E. Olson,et al.  microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. , 2008, Genes & development.

[73]  D. Rueckert,et al.  Automated analysis of atrial late gadolinium enhancement imaging that correlates with endocardial voltage and clinical outcomes: A 2-center study , 2013, Heart rhythm.

[74]  Bharath Ambale-Venkatesh,et al.  Cardiac MRI: a central prognostic tool in myocardial fibrosis , 2015, Nature Reviews Cardiology.

[75]  J. Mariani,et al.  Relationship of circulating matrix biomarkers to myocardial matrix metabolism in advanced heart failure , 2013, European journal of heart failure.

[76]  M. de Antonio,et al.  Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. , 2014, Journal of the American College of Cardiology.

[77]  S. Nattel,et al.  MicroRNA29: A Mechanistic Contributor and Potential Biomarker in Atrial Fibrillation , 2013, Circulation.

[78]  MartaRuiz-Ortega,et al.  Angiotensin II Activates the Smad Pathway in Vascular Smooth Muscle Cells by a Transforming Growth Factor-β–Independent Mechanism , 2005 .

[79]  Yenn-Jiang Lin,et al.  Inflammation and the pathogenesis of atrial fibrillation , 2015, Nature Reviews Cardiology.

[80]  Sander Verheule,et al.  Increased Vulnerability to Atrial Fibrillation in Transgenic Mice With Selective Atrial Fibrosis Caused by Overexpression of TGF-β1 , 2004, Circulation research.

[81]  A. Malhotra,et al.  Effect of Sleep Apnea and Continuous Positive Airway Pressure on Cardiac Structure and Recurrence of Atrial Fibrillation , 2013, Journal of the American Heart Association.

[82]  H. Duffy,et al.  Fibroblasts and Myofibroblasts: What Are We Talking About? , 2011, Journal of cardiovascular pharmacology.

[83]  S. Grajek,et al.  Impact of atrial remodeling on heart rhythm after radiofrequency ablation and mitral valve operations. , 2012, The Annals of thoracic surgery.

[84]  P. Vardas,et al.  Angiotensin II Type 1 Receptor Inhibition is Associated with Reduced Tachyarrhythmia-Induced Ventricular Interstitial Fibrosis in a Goat Atrial Fibrillation Model , 2007, Cardiovascular Drugs and Therapy.

[85]  J. Garot,et al.  Correlation between AF Substrate Ablation Difficulty and Left Atrial Fibrosis Quantified by Delayed‐Enhancement Cardiac Magnetic Resonance , 2011, Pacing and clinical electrophysiology : PACE.

[86]  Jeffrey E. Thatcher,et al.  Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis , 2008, Proceedings of the National Academy of Sciences.

[87]  A. Leask Potential Therapeutic Targets for Cardiac Fibrosis: TGF&bgr;, Angiotensin, Endothelin, CCN2, and PDGF, Partners in Fibroblast Activation , 2010, Circulation research.

[88]  T. Doetschman,et al.  Origin of Cardiac Fibroblasts and the Role of Periostin , 2009, Circulation research.

[89]  P. Nilsson,et al.  Body weight and risk of atrial fibrillation in 7,169 patients with newly diagnosed type 2 diabetes; an observational study , 2015, Cardiovascular Diabetology.

[90]  Yong Li,et al.  Increased Expression of Connective Tissue Growth Factor and Transforming Growth Factor-Beta-1 in Atrial Myocardium of Patients with Chronic Atrial Fibrillation , 2013, Cardiology.

[91]  M. Pisano,et al.  Intracellular dynamics of Smad‐mediated TGFβ signaling , 2003 .

[92]  Jeroen J. Bax,et al.  Impact of left atrial fibrosis and left atrial size on the outcome of catheter ablation for atrial fibrillation , 2011, Heart.

[93]  Markus Grube,et al.  Rac1-induced connective tissue growth factor regulates connexin 43 and N-cadherin expression in atrial fibrillation. , 2010, Journal of the American College of Cardiology.

[94]  S. Conway,et al.  The Dynamic Role of Cardiac Fibroblasts in Development and Disease , 2012, Journal of Cardiovascular Translational Research.

[95]  R. Mahajan,et al.  The implications of obesity for cardiac arrhythmia mechanisms and management. , 2015, The Canadian journal of cardiology.

[96]  A. Feldman,et al.  Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. , 2000, Cardiovascular research.

[97]  E. Kholmovski,et al.  Atrial Fibrosis Helps Select the Appropriate Patient and Strategy in Catheter Ablation of Atrial Fibrillation: A DE‐MRI Guided Approach , 2011, Journal of cardiovascular electrophysiology.

[98]  I. V. Van Gelder,et al.  New risk factors for atrial fibrillation: causes of 'not-so-lone atrial fibrillation'. , 2008, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[99]  M. Volpe,et al.  Role of the renin-angiotensin-aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction. , 2009, Clinical science.

[100]  Seung‐Jung Park,et al.  Transforming growth factor β1-mediated atrial fibrotic activity and the recovery of atrial mechanical contraction after surgical maze procedure. , 2013, International journal of cardiology.

[101]  F. Spinale,et al.  Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. , 1998, Circulation research.

[102]  P. Schauerte,et al.  Decreased Plasminogen Activator Inhibitor and Tissue Metalloproteinase Inhibitor Expression May Promote Increased Metalloproteinase Activity with Increasing Duration of Human Atrial Fibrillation , 2007, Journal of cardiovascular electrophysiology.

[103]  Christopher McGann,et al.  Atrial Fibrillation Ablation Outcome Is Predicted by Left Atrial Remodeling on MRI , 2014, Circulation. Arrhythmia and electrophysiology.

[104]  V. Shusterman,et al.  Atrial contractile dysfunction, fibrosis, and arrhythmias in a mouse model of cardiomyopathy secondary to cardiac-specific overexpression of tumor necrosis factor-{alpha}. , 2005, American journal of physiology. Heart and circulatory physiology.

[105]  R. Kalluri,et al.  The origin of fibroblasts and mechanism of cardiac fibrosis , 2010, Journal of cellular physiology.

[106]  A. McLellan,et al.  Diffuse Ventricular Fibrosis Measured by T1 Mapping on Cardiac MRI Predicts Success of Catheter Ablation for Atrial Fibrillation , 2014, Circulation. Arrhythmia and electrophysiology.

[107]  H. Hermeking,et al.  MicroRNA-34a regulates cardiac ageing and function , 2013, Nature.

[108]  D. Bartel MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[109]  Richard T. Lee,et al.  Intramyocardial Fibroblast Myocyte Communication , 2010, Circulation research.

[110]  G. Hindricks,et al.  Galectin-3 in Patients with Atrial Fibrillation Undergoing Radiofrequency Catheter Ablation , 2015, PloS one.

[111]  E. Kholmovski,et al.  Evaluation of the left atrial substrate in patients with lone atrial fibrillation using delayed-enhanced MRI: implications for disease progression and response to catheter ablation. , 2010, Heart rhythm.

[112]  A. Oto,et al.  A Prospective DE‐MRI Study Evaluating the Role of TGF‐β1 in Left Atrial Fibrosis and Implications for Outcomes of Cryoballoon‐Based Catheter Ablation: New Insights into Primary Fibrotic Atriocardiomyopathy , 2015, Journal of cardiovascular electrophysiology.

[113]  Y. Okumura,et al.  Impact of Biomarkers of Inflammation and Extracellular Matrix Turnover on the Outcome of Atrial Fibrillation Ablation: Importance of Matrix Metalloproteinase‐2 as a Predictor of Atrial Fibrillation Recurrence , 2011, Journal of cardiovascular electrophysiology.

[114]  Yijiang Chen,et al.  Osteoprotegerin/RANK/RANKL axis and atrial remodeling in mitral valvular patients with atrial fibrillation. , 2013, International journal of cardiology.

[115]  R. Blankstein,et al.  The incidence, pattern, and prognostic value of left ventricular myocardial scar by late gadolinium enhancement in patients with atrial fibrillation . , 2013, Journal of the American College of Cardiology.

[116]  Alexandru B. Chicos,et al.  Atrial and ventricular fibrosis induced by atrial fibrillation: evidence to support early rhythm control. , 2008, Heart rhythm.

[117]  R. Sheppard,et al.  Fibrosis in heart disease: understanding the role of transforming growth factor‐β1 in cardiomyopathy, valvular disease and arrhythmia , 2006, Immunology.

[118]  B. Kalionis,et al.  The Role of Oxidative Stress and Inflammation in Cardiovascular Aging , 2014, BioMed research international.

[119]  J. Olgin,et al.  Molecular basis of selective atrial fibrosis due to overexpression of transforming growth factor-β1. , 2013, Cardiovascular research.

[120]  Jérôme Kalifa,et al.  Risk Factors and Genetics of Atrial Fibrillation. , 2016, Heart failure clinics.

[121]  R. Kalluri,et al.  Origins of cardiac fibroblasts. , 2010, Circulation research.

[122]  L. Tokgozoglu,et al.  Effects of persistent atrial fibrillation on serum galectin-3 levels. , 2015, The American journal of cardiology.

[123]  Christopher McGann,et al.  Echocardiographic left atrial reverse remodeling after catheter ablation of atrial fibrillation is predicted by preablation delayed enhancement of left atrium by magnetic resonance imaging. , 2010, American heart journal.

[124]  Shufeng Zhou,et al.  Activated nuclear factor-κB and increased tumor necrosis factor-α in atrial tissue of atrial fibrillation , 2009, Scandinavian cardiovascular journal : SCJ.

[125]  P. Vardas,et al.  Extracellular matrix alterations in patients with paroxysmal and persistent atrial fibrillation: biochemical assessment of collagen type-I turnover. , 2008, Journal of the American College of Cardiology.

[126]  D. McManus,et al.  Atrial fibrillation and heart failure parallels: lessons for atrial fibrillation prevention. , 2011, Critical pathways in cardiology.

[127]  G. Nuovo,et al.  MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. , 2009, Cardiovascular research.

[128]  Zhouqin Jiang,et al.  Association Between C‐Reactive Protein and Atrial Fibrillation Recurrence After Catheter Ablation: A Meta‐analysis , 2013, Clinical cardiology.

[129]  G. Lip,et al.  Left ventricular fibrosis in atrial fibrillation. , 2013, The American journal of cardiology.

[130]  T. Marwick,et al.  Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade , 2013, Heart.

[131]  G. Lip,et al.  Role of microRNAs in cardiac remodelling: new insights and future perspectives. , 2013, International journal of cardiology.

[132]  U. Laufs,et al.  Role of miR-21 in the pathogenesis of atrial fibrosis , 2012, Basic Research in Cardiology.

[133]  Hui Chen,et al.  Relationship Between Integrated Backscatter and Atrial Fibrosis in Patients with and Without Atrial Fibrillation Who Are Undergoing Coronary Bypass Surgery , 2009, Clinical cardiology.

[134]  M. Yacoub,et al.  Functional crosstalk between cardiac fibroblasts and adult cardiomyocytes by soluble mediators. , 2015, Cardiovascular research.

[135]  T. Munzel,et al.  Atrial fibrosis and atrial fibrillation: the role of the TGF-β1 signaling pathway. , 2010, International journal of cardiology.

[136]  D. Kaye,et al.  Histological validation of cardiac magnetic resonance analysis of regional and diffuse interstitial myocardial fibrosis. , 2015, European heart journal cardiovascular Imaging.

[137]  A. Ballestrero,et al.  Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidase. , 2006, Cardiovascular research.

[138]  W. Daniel,et al.  Atrial distribution of connexin 40 and 43 in patients with intermittent, persistent, and postoperative atrial fibrillation. , 2006, Heart, lung & circulation.

[139]  R. Fenici,et al.  Cardiac biopsy in patients with "primary" atrial fibrillation. Histologic evidence of occult myocardial diseases. , 1991, Chest.

[140]  J. Jalife Mechanisms of persistent atrial fibrillation , 2014, Current opinion in cardiology.

[141]  A. Camm,et al.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, European heart journal.

[142]  Paul A. Overbeek,et al.  TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice , 2000, Nature Medicine.

[143]  Nolwenn Le Meur,et al.  Contrasting Gene Expression Profiles in Two Canine Models of Atrial Fibrillation , 2007, Circulation research.

[144]  D. Haines,et al.  Electrical, Morphological, and Ultrastructural Remodeling and Reverse Remodeling in a Canine Model of Chronic Atrial Fibrillation , 2000, Circulation.

[145]  Stephanie L. K. Bowers,et al.  Cardiac Fibroblast: The Renaissance Cell , 2009, Circulation research.

[146]  J. Risteli,et al.  Atrial extracellular matrix remodelling in patients with atrial fibrillation , 2007, Journal of cellular and molecular medicine.

[147]  K. Nishigaki,et al.  Left atrial pathological degeneration assessed by integrated backscatter transesophageal echocardiography as a predictor of progression to persistent atrial fibrillation: Results from a prospective study of three-years follow-up , 2012, Cardiovascular Ultrasound.

[148]  Ichiro Manabe,et al.  Cellular Interplay between Cardiomyocytes and Nonmyocytes in Cardiac Remodeling , 2011, International journal of inflammation.